Lymphoblastic Lymphoma

  • Birgit Burkhardt
  • Birte WistinghausenEmail author


Lymphoblastic lymphoma (LBL) is the second most common type of non-Hodgkin lymphoma (NHL) in childhood and adolescence accounting for 25–35% of all cases. The majority, 70–80%, is of T-lymphoblastic origin, and 20–25% arise from B-lymphoblasts. With intensification of therapy in the last decades, the event-free and overall survivals for pediatric LBL patients are now exceeding 80%, but the burden of therapy causes considerable morbidity and late sequela. In addition, the prognosis of relapsed patients remains poor (Schmidt and Burkhardt. Pediatr Hematol Oncol. 30:484–508, 2013). This chapter will focus on the pathogenesis and biology of LBL, recent advances in the therapy of LBL, and ongoing and future efforts in optimizing therapy and developing novel targeted treatment approaches.


Lymphoblastic lymphoma Precursor T cell Precursor B cell Children Adolescents 


  1. 1.
    Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013;30(6):484–508.PubMedCrossRefGoogle Scholar
  2. 2.
    Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013;162(6):792–801.CrossRefGoogle Scholar
  3. 3.
    Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017;102(12):2086–96.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49.CrossRefGoogle Scholar
  5. 5.
    Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, d’Amore ES, Szczepanowski M, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children’s Oncology Group report. Br J Haematol. 2012;159(4):454–61.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Ducassou S, Ferlay C, Bergeron C, Girard S, Laureys G, Pacquement H, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011;152(4):441–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35(1):20–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.PubMedGoogle Scholar
  10. 10.
    Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Borowitz MJC, J KC, Downing JR, Le Beau MM, Arber DA. Precursor lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Plieri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 200–13.Google Scholar
  12. 12.
    Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82–93.PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12(6):344–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol. 2010;149(5):653–68.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Basso K, Mussolin L, Lettieri A, Brahmachary M, Lim WK, Califano A, et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011;50(12):1063–75.CrossRefGoogle Scholar
  16. 16.
    Uyttebroeck A, Vanhentenrijk V, Hagemeijer A, Boeckx N, Renard M, Wlodarska I, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9):1745–54.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Oschlies I, Burkhardt B, Chassagne-Clement C, d’Amore ES, Hansson U, Hebeda K, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011;35(6):836–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Smock KJ, Nelson M, Tripp SR, Sanger WG, Abromowitch M, Cairo MS, et al. Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(4):489–94.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–63.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol. 2015;144(3):411–22.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20(4):369–73.PubMedCrossRefGoogle Scholar
  23. 23.
    Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421–4.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissue. Lyon: IARC; 2008.Google Scholar
  25. 25.
    Matutes E, Pickl WF, Van’t Veer M, Morilla R, Swansbury J, Strobl H, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117(11):3163–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Boddu P, Yin CC, Kanagal-Shamanna R, Tang G, Thakral B, Kadia T, et al. An Unsuspected Finding of t(9;22): a rare case of Philadelphia chromosome-positive b-lymphoblastic lymphoma. Case Rep Hematol. 2017;2017:2413587.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Ahlmann M, Meyer C, Marschalek R, Burkhardt B, Koehler G, Klapper W, et al. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma. Eur J Haematol. 2014;93(4):349–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Maitra A, McKenna RW, Weinberg AG, Schneider NR, Kroft SH. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol. 2001;115(6):868–75.PubMedCrossRefGoogle Scholar
  29. 29.
    Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O’Brien S, et al. Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge. Clin Lymphoma Myeloma Leuk. 2014;14(4):e115–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017;64(7) Scholar
  31. 31.
    Burkhardt B, Bruch J, Zimmermann M, Strauch K, Parwaresch R, Ludwig WD, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006;20(8):1422–9.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Lones MA, Heerema NA, Le Beau MM, Sposto R, Perkins SL, Kadin ME, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer GenetCytogenet. 2007;172(1):1–11.CrossRefGoogle Scholar
  33. 33.
    Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G, et al. Activating NOTCH1 mutations predict favorable early treatment response and long term outcome in child-hood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010;24(12):2005–13.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Bonn BR, Rohde M, Zimmermann M, Krieger D, Oschlies I, Niggli F, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood. 2013;121(16):3153–60.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012;30(16):1966–73.CrossRefGoogle Scholar
  37. 37.
    Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145(2):198–206.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008;14(3):692–700.CrossRefGoogle Scholar
  39. 39.
    Burkhardt B, Moericke A, Klapper W, Greene F, Salzburg J, Damm-Welk C, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. LeukLymphoma. 2008;49(3):451–61.Google Scholar
  40. 40.
    Balbach ST, Makarova O, Bonn BR, Zimmermann M, Rohde M, Oschlies I, et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2016;30(4):970–3.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96.PubMedCrossRefGoogle Scholar
  42. 42.
    Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2014;26(1):149–61.PubMedCrossRefGoogle Scholar
  43. 43.
    Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica. 2013;98(6):928–36.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, Cazzaniga G, et al. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols. Br J Haematol. 2018;182(5):705–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, Kooi C, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3816–23.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Yang YL, Hsiao CC, Chen HY, Lin KH, Jou ST, Chen JS, et al. Absence of biallelic TCRgamma deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(6):846–51.PubMedCrossRefGoogle Scholar
  48. 48.
    Pomari E, Lovisa F, Carraro E, Primerano S, D’Amore ESG, Bonvini P, et al. Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma. Oncotarget. 2017;8(64):107886–98.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173(4):545–59.CrossRefGoogle Scholar
  50. 50.
    Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13(6):1368–76.PubMedCrossRefGoogle Scholar
  51. 51.
    Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, Meinhardt A, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153–60.CrossRefGoogle Scholar
  52. 52.
    Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44(6):840–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children’s Oncology Group trial A5971: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1229–33.PubMedCrossRefGoogle Scholar
  54. 54.
    Stark B, Avigad S, Luria D, Manor S, Reshef-Ronen T, Avrahami G, et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer. 2009;52(1):20–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J Clin Oncol. 2009;27(21):3533–9.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Mussolin L, Buldini B, Lovisa F, Carraro E, Disaro S, Nigro LL, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience. Pediatr Blood Cancer. 2015;62(11):1906–13.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Bardi E, Csoka M, Garai I, Szegedi I, Muller J, Gyorke T, et al. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathol Oncol Res. 2014;20(1):139–43.PubMedCrossRefGoogle Scholar
  58. 58.
    Nakatani K, Nakamoto Y, Watanabe K, Saga T, Higashi T, Togashi K. Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma. Clin Nucl Med. 2012;37(7):656–62.PubMedCrossRefGoogle Scholar
  59. 59.
    Riad R, Omar W, Kotb M, Hafez M, Sidhom I, Zamzam M, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(2):319–29.PubMedCrossRefGoogle Scholar
  60. 60.
    Riad R, Omar W, Sidhom I, Zamzam M, Zaky I, Hafez M, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun. 2010;31(3):232–8.CrossRefGoogle Scholar
  61. 61.
    Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr. 2013;172(6):733–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015;33(18):2112–8.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Wollner N, Burchenal JH, Lieberman PH, Exelby P, D’Angio G, Murphy ML. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976;37(1):123–34.PubMedCrossRefGoogle Scholar
  65. 65.
    Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979;44(6):1990–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359–72.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416–21.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Jin L, Zhang R, Huang S, Yang J, Duan YL, Zhang YH. Clinical features and prognosis of children with lymphoblastic lymphoma. Zhonghua Zhong Liu Za Zhi. 2012;34(2):138–42.PubMedGoogle Scholar
  69. 69.
    Kobayashi R, Takimoto T, Nakazawa A, Fujita N, Akazai A, Yamato K, et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. Int J Hematol. 2014;99(6):743–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Sun XF, Xia ZJ, Zhen ZJ, Xiang XJ, Xia Y, Ling JY, et al. Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma. Int J Clin Oncol. 2008;13(5):436–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Gao YJ, Pan C, Tang JY, Lu FJ, Chen J, Xue HL, et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010. Pediatr Blood Cancer. 2014;61(4):659–63.PubMedCrossRefGoogle Scholar
  72. 72.
    Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Fukano R, et al. Prognostic impact of intensified maintenance therapy on children with advanced lymphoblastic lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 study. Pediatr Blood Cancer. 2016;63(3):451–7.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Patte C, Kalifa C, Flamant F, Hartmann O, Brugieres L, Valteau-Couanet D, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20(2):105–13.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874–83.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Sterba J, Kovacs G, Matus M, Bubanska E, Kyr M, Krenova Z, et al. Capizzi methotrexate with BFM backbone without craniospinal irradiation is effective treatment for pediatric lymphoblastic lymphoma: results from 5 countries with I-BFM LL 09 protocol. Br J Haematol. 2015;171(Suppl. 1):33.Google Scholar
  76. 76.
    Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36(29):2926–34. Scholar
  77. 77.
    Dunsmore KP, Winter S, Devidas M, Wood BL, Esiashvili N, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema N, Asselin B, Rabin KR, Zweidler-McKay P, Raetz RA, Loh ML, Winick NJ, Carroll WL, Hunger S. COG AALL0434: a randomized trial testing nelarabine in newly diagnosed t-cell malignancy. J Clin Oncol. 2018;36:10500.CrossRefGoogle Scholar
  78. 78.
    Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009;52:591.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2009;16(2):223–30.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Burkhardt B, Zimmermann M, Oschlies I, Klapper W, Meinhardt A, Landmann E, et al., editors. Outcome of adolescents with non-Hodgkin lymphoma in the BFM studies: relevance of gender and histological subtype. In: 3rd international symposium on childhood, adolescent and young adult non-Hodgkin’s Lymphoma, Frankfurt: Hematology meeting reports; June 2009.Google Scholar
  81. 81.
    Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13(6):709–14.PubMedCrossRefGoogle Scholar
  82. 82.
    Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580–8.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Delgado-Martin C, Meyer LK, Huang BJ, Shimano KA, Zinter MS, Nguyen JV, et al. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. Leukemia. 2017;31(12):2568–76.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131(9):995–9.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, et al. Preclinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica. 2019;104(1):e17–20.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–42.PubMedCrossRefGoogle Scholar
  87. 87.
    Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491–9.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143(2):261–7.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Abromowitch M, Termuhlen A, Chang M, Perkins S, Gross T, Weinstein H, et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Blood. 2008;12:Abstract No. 3610.Google Scholar
  90. 90.
    Pillon M, Piglione M, Garaventa A, Conter V, Giuliano M, Arcamone G, et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of pediatric hematology and oncology. Pediatr Blood Cancer. 2009;53(6):953–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23(6):1127–30.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Uyttebroeck A, Suciu S, Plat G, Laureys G, Costa V, Rohrlich P, et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012;159(Suppl. 1):37.Google Scholar
  93. 93.
    Bergeron C, Coze C, Segura C, Pacquement H, Gandemer V, Ducassou S, et al. Treatment of childhood T-cell lymphoblastic lymphoma-long-term results of the SFOP LMT96 trial. Pediatr Blood Cancer. 2015;62(12):2150–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pediatric Hematology and OncologyUniversity Hospital MünsterMünsterGermany
  2. 2.Division of OncologyCenter for Cancer and Blood Disorders, Children’s National Medical Center, The George Washington University School of MedicineWashington, DCUSA

Personalised recommendations